Use of a Combination of Clozapine With a Long-Acting Injectable Antipsychotic: A Retrospective Study.

IF 2.9 3区 医学 Q2 PHARMACOLOGY & PHARMACY
Journal of Clinical Psychopharmacology Pub Date : 2026-09-01 Epub Date: 2026-04-03 DOI:10.1097/JCP.0000000000002177
Sandeep Grover, Jyotika Kanwar, Subho Chakrabarti
{"title":"Use of a Combination of Clozapine With a Long-Acting Injectable Antipsychotic: A Retrospective Study.","authors":"Sandeep Grover, Jyotika Kanwar, Subho Chakrabarti","doi":"10.1097/JCP.0000000000002177","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>About one-third of patients fail to respond to clozapine and require augmentation. Among the various augmentation strategies, the use of long-acting injectable (LAI) antipsychotics has been evaluated in a few studies, but the data remain inconclusive. Furthermore, there is a lack of data on the use of a combination of clozapine and LAI from developed countries. This retrospective study aimed to evaluate the impact of clozapine and LAI combination on symptom profile, rehospitalization rate, and functioning in the Indian setting.</p><p><strong>Methods: </strong>For this study, treatment records of patients on clozapine were reviewed for the use of a combination of clozapine and an LAI antipsychotic. Patients who had received a combination of clozapine and LAI were included in this study. The information available in the treatment records was used to rate the patients on the clinical global improvement (CGI) scale retrospectively to evaluate the beneficial effect of the combination.</p><p><strong>Results: </strong>Out of the 1102 patients who received clozapine while in contact with our services, 13 patients had received a combination of clozapine and an LAI. In 8 patients, LAI was started after an adequate clozapine trial, and in 5 patients, clozapine was added to the ongoing LAI antipsychotic medication. At 3 months, 12 patients were rated as \"much improved,\" and 1 patient was rated as \"very much improved\" on the CGI. At the last follow-up assessment, at 6 months to 6 years, the improvement was rated as \"very much improved\" for 9 patients, and \"much improved\" for 3 patients. While on the combination, only 2 patients required further inpatient care. The combination also led to a reduction in the number of relapses and an improvement in functioning.</p><p><strong>Conclusions: </strong>The present study suggests that combining LAI with clozapine leads to improvement in psychopathology and functioning.</p>","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":"603-607"},"PeriodicalIF":2.9000,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Psychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/JCP.0000000000002177","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/4/3 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: About one-third of patients fail to respond to clozapine and require augmentation. Among the various augmentation strategies, the use of long-acting injectable (LAI) antipsychotics has been evaluated in a few studies, but the data remain inconclusive. Furthermore, there is a lack of data on the use of a combination of clozapine and LAI from developed countries. This retrospective study aimed to evaluate the impact of clozapine and LAI combination on symptom profile, rehospitalization rate, and functioning in the Indian setting.

Methods: For this study, treatment records of patients on clozapine were reviewed for the use of a combination of clozapine and an LAI antipsychotic. Patients who had received a combination of clozapine and LAI were included in this study. The information available in the treatment records was used to rate the patients on the clinical global improvement (CGI) scale retrospectively to evaluate the beneficial effect of the combination.

Results: Out of the 1102 patients who received clozapine while in contact with our services, 13 patients had received a combination of clozapine and an LAI. In 8 patients, LAI was started after an adequate clozapine trial, and in 5 patients, clozapine was added to the ongoing LAI antipsychotic medication. At 3 months, 12 patients were rated as "much improved," and 1 patient was rated as "very much improved" on the CGI. At the last follow-up assessment, at 6 months to 6 years, the improvement was rated as "very much improved" for 9 patients, and "much improved" for 3 patients. While on the combination, only 2 patients required further inpatient care. The combination also led to a reduction in the number of relapses and an improvement in functioning.

Conclusions: The present study suggests that combining LAI with clozapine leads to improvement in psychopathology and functioning.

氯氮平与长效注射抗精神病药物联合使用的回顾性研究。
背景:约三分之一的患者对氯氮平无效,需要强化治疗。在各种增强策略中,一些研究评估了长效注射(LAI)抗精神病药物的使用,但数据仍不确定。此外,缺乏发达国家氯氮平和LAI联合使用的数据。本回顾性研究旨在评估氯氮平和LAI联合使用对印度患者症状特征、再住院率和功能的影响。方法:本研究回顾氯氮平患者联合使用氯氮平和LAI抗精神病药的治疗记录。接受氯氮平和LAI联合治疗的患者被纳入本研究。治疗记录中可用的信息用于回顾性地对患者进行临床总体改善(CGI)评分,以评估联合治疗的有益效果。结果:在1102名接受氯氮平治疗的患者中,13名患者接受了氯氮平和LAI的联合治疗。8例患者在充分的氯氮平试验后开始LAI, 5例患者在持续的LAI抗精神病药物中加入氯氮平。3个月时,12名患者在CGI上被评为“非常改善”,1名患者被评为“非常改善”。在6个月至6年的最后一次随访评估中,9例患者的改善被评为“非常改善”,3例患者的改善被评为“非常改善”。在联合用药时,只有2例患者需要进一步住院治疗。这种结合也减少了复发的次数,改善了功能。结论:本研究提示LAI联合氯氮平可改善精神病理和功能。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.00
自引率
3.40%
发文量
231
审稿时长
4-8 weeks
期刊介绍: Journal of Clinical Psychopharmacology, a leading publication in psychopharmacology, offers a wide range of articles reporting on clinical trials and studies, side effects, drug interactions, overdose management, pharmacogenetics, pharmacokinetics, and psychiatric effects of non-psychiatric drugs. The journal keeps clinician-scientists and trainees up-to-date on the latest clinical developments in psychopharmacologic agents, presenting the extensive coverage needed to keep up with every development in this fast-growing field.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书